Join our daily newsletter At The Bell to receive exclusive market insights
- Medical technology company Osteopore (OSX) signs an exclusive distribution agreement with MAXONIQ to market and sell its products in Australia and New Zealand
- Under the three-year agreement, MAXONIQ will market and sell Osteopore’s Osteomesh product for use in orbital floor reconstruction surgery
- Osteopore will work closely with MAXONIQ to train and support sales representatives to facilitate promotions across Australia and New Zealand
- This partnership forms part of Osteopore’s initiatives to increase the global accessibility of its products
- Shares in Osteopore are up 2.78 per cent on market close and trading at 18.5 cents
Medical technology company Osteopore (OSX) has signed an exclusive distribution agreement with MAXONIQ to market and sell its products in Australia and New Zealand.
Based in Australia, MAXONIQ specialises in solutions for complex oral and maxillofacial applications.
Under the three-year agreement, MAXONIQ will market and sell Osteopore’s Osteomesh product for use in orbital floor reconstruction surgery.
Osteopore will work closely with MAXONIQ to train and support sales representatives to facilitate promotions across Australia and New Zealand.
“We are excited by the exclusive distribution opportunity with Osteopore in Australia and New Zealand and the Oral and Maxillofacial (OMF) surgical market,” MAXONIQ Managing Director Stuart Douglas said.
“The partnership with Osteopore will allow focused specialist representation of Osteomesh for orbital floor repair and facilitate sales of Patient-Specific Implants for orbit reconstruction.”
This partnership forms part of Osteopore’s initiatives to increase the global accessibility of its products.
Partnerships with companies in Spain and Colombia have already started generating revenues.
“This MAXONIQ partnership will help strengthen our reach beyond the cranial space into the OMF area where our solutions have been successfully adopted in Asia, Executive Chairman Mark Leong said.
“This also helps us gain a deeper foothold into our home market of Australia.”
Shares in Osteopore were up 2.78 per cent on market close and trading at 18.5 cents.
